• TechCrunch
• CrunchBase
• More
  • TechCrunch UK
  • TechCrunch France
  • TechCrunch Japan

Virobay

edit

Virobay, Inc. operates as an anti-viral drug discovery and development company. It engages in developing, investigating, and creating treatments for hepatitis C, such as protease and polymerase inhibitors. The company was founded in 2006 and is headquartered in Menlo Park, California.

Milestones

edit

• 
  Virobay added David B. Karpf as Chief Medical Officer.
  Posted 11/3/11 at 6:54pm
• 
  Virobay added Robert Booth as CEO.
  Posted 11/3/11 at 6:54pm
• 
  Virobay added Heather Preston as Board of Directors.
  Posted 1/20/10 at 8:07pm
• 
  Virobay received $10M in Unattributed funding. (6/16/10)
  Posted 6/17/10 at 5:38pm via venturebeat.com
• 
  Virobay received $300k in Debt funding. (1/14/10)
  Posted 1/20/10 at 8:07pm via venturebeat.com

Videos

Screenshots

edit

Above: Home Page
Uploaded: 1/21/10

Sources

1. Virobay raises $300K to treat hepatitis C and autoimmune disorders (deals.venturebeat.com) [edit]
2. Drug developer Virobay secures $10M for hepatitis C treatments (deals.venturebeat.com) [edit]